A carregar...
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox dru...
Na minha lista:
| Publicado no: | Cancer Cell |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5161231/ https://ncbi.nlm.nih.gov/pubmed/27960087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.11.006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|